These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28198785)

  • 61. RESOLUTION OF SUBRETINAL FLUID AND OUTER RETINAL CHANGES IN PATIENTS TREATED WITH OCRIPLASMIN.
    Nudleman E; Franklin MS; Wolfe JD; Williams GA; Ruby AJ
    Retina; 2016 Apr; 36(4):738-43. PubMed ID: 26398688
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes.
    Sharma P; Juhn A; Houston SK; Fineman M; Chiang A; Ho A; Regillo C
    Am J Ophthalmol; 2015 May; 159(5):861-7.e2. PubMed ID: 25660387
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Delayed full-thickness macular hole closure without vitreomacular traction release following ocriplasmin injection.
    Abou Ltaif S; Herbert L
    BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26359463
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The efficacy and safety of ocriplasmin for patients with vitreous macular traction.
    Zhang WF; Zhao XY; Meng LH; Wang DY; Feng S; Chen YX
    Acta Ophthalmol; 2022 Feb; 100(1):e304-e313. PubMed ID: 34021702
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of ocriplasmin on the management of macular holes: assessment of the clinical relevance of ocriplasmin.
    Moisseiev J; Moroz I; Katz G
    JAMA Ophthalmol; 2014 Jun; 132(6):709-13. PubMed ID: 24723009
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Chronic Serous Macular Detachments and Visual Disturbance Complicating Consecutive Cases of Symptomatic Vitreomacular Adhesion With Macular Hole Treated With Ocriplasmin.
    Luttrull JK
    Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):976-8. PubMed ID: 26469240
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Predicting the individual probability of macular hole closure following intravitreal ocriplasmin injections for vitreomacular traction release using baseline characteristics.
    Bertelmann T; Berndzen L; Raber T; Pfeiffer S; Leha A; Paul C; Feltgen N; Bemme S
    Sci Rep; 2021 Dec; 11(1):24096. PubMed ID: 34916576
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Clinical evaluation of ocriplasmin as a vitreolytic agent].
    Li L; Du H; Li M; Hui Y
    Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):155-60. PubMed ID: 25908008
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Acute panretinal structural and functional abnormalities after intravitreous ocriplasmin injection.
    Fahim AT; Khan NW; Johnson MW
    JAMA Ophthalmol; 2014 Apr; 132(4):484-6. PubMed ID: 24577241
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Retinal detachment after intravitreal ocriplasmin injection].
    Müller M; Koch F; Singh P; Kohnen T
    Ophthalmologe; 2021 Jan; 118(1):56-59. PubMed ID: 32274532
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Research update of ocriplasmin for symptomatic vitreomacular adhesion].
    Zhang M; Chen Y
    Zhonghua Yan Ke Za Zhi; 2014 Nov; 50(11):866-70. PubMed ID: 25582211
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Unclear retinopathy after intravitreal injection of ocriplasmin].
    Abraham S; Wand K; Stumpfe S; Feucht N; Lohmann CP; Maier M
    Ophthalmologe; 2016 Feb; 113(2):156-9. PubMed ID: 26205745
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Safety profile of ocriplasmin for the pharmacologic treatment of symptomatic vitreomacular adhesion/traction.
    Kaiser PK; Kampik A; Kuppermann BD; Girach A; Rizzo S; Sergott RC
    Retina; 2015 Jun; 35(6):1111-27. PubMed ID: 25635577
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Impact of vitreomacular adhesion on ranibizumab mono- and combination therapy for neovascular age-related macular degeneration.
    Waldstein SM; Ritter M; Simader C; Mayr-Sponer U; Kundi M; Schmidt-Erfurth U
    Am J Ophthalmol; 2014 Aug; 158(2):328-336.e1. PubMed ID: 24794282
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Ocriplasmin: a review of its use in patients with symptomatic vitreomacular adhesion.
    Syed YY; Dhillon S
    Drugs; 2013 Sep; 73(14):1617-25. PubMed ID: 24062204
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The predictability of ocriplasmin treatment effects: is there consensus among retinal experts? Results from the EXPORT study.
    Bertelmann T; Wachtlin J; Mennel S; Koss MJ; Maier MM; Schumann RG; Kazerounian S; Daniel H; Schmitz-Valckenberg S;
    Graefes Arch Clin Exp Ophthalmol; 2017 Jul; 255(7):1359-1367. PubMed ID: 28389700
    [TBL] [Abstract][Full Text] [Related]  

  • 77. SAFETY PROFILE OF OCRIPLASMIN FOR SYMPTOMATIC VITREOMACULAR ADHESION: A Comprehensive Analysis of Premarketing and Postmarketing Experiences.
    Hahn P; Chung MM; Flynn HW; Huang SS; Kim JE; Mahmoud TH; Sadda SR; Dugel PU
    Retina; 2015 Jun; 35(6):1128-34. PubMed ID: 25635575
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Initial outcomes following intravitreal ocriplasmin for treatment of symptomatic vitreomacular adhesion.
    Kim BT; Schwartz SG; Smiddy WE; Doshi RR; Kovach JL; Berrocal AM; Moshfeghi AA; Fortun JA
    Ophthalmic Surg Lasers Imaging Retina; 2013; 44(4):334-43. PubMed ID: 23883268
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Early evolution of the vitreomacular interface and clinical efficacy after ocriplasmin injection for symptomatic vitreomacular adhesion.
    Meyer JC; Shah GK; Blinder KJ; Waheed NK; Reichel E; Stalmans P; Singer M; Tewari A
    Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):209-16. PubMed ID: 25707046
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Vision loss after intravitreal ocriplasmin: correlation of spectral-domain optical coherence tomography and electroretinography.
    Tibbetts MD; Reichel E; Witkin AJ
    JAMA Ophthalmol; 2014 Apr; 132(4):487-90. PubMed ID: 24577286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.